Home » US FDA’s Safe Use Initiative May Increase REMS
US FDA’s Safe Use Initiative May Increase REMS
November 16, 2009
Drugmakers may see a rise in the number of required risk evaluation and mitigation strategies (REMS) required by the U.S. Food and Drug Administration
(FDA) under its Safe Use Initiative launched this month.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor